AnnaLynn M Williams, Wei Liu, Matthew J Ehrhardt, Sedigheh Mirzaei Salehabadi, Angela Panoskaltsis-Mortari, Nicholas S Phillips, Daniel A Mulrooney, Jamie E Flerlage, Yutaka Yasui, Deo Kumar Srivastava, Leslie L Robison, Melissa M Hudson, Kirsten K Ness, Noah D Sabin, Kevin R Krull
BACKGROUND: Hodgkin lymphoma (HL) survivors experience neurocognitive impairment despite receiving no central nervous system-directed therapy, though little is known about underlying mechanisms. METHODS: HL survivors (n=197) and age-, sex- and race/ethnicity-frequency-matched community controls (n=199) underwent standardized neurocognitive testing, and serum collection. Luminex multiplex or ELISA assays measured markers of inflammation and oxidative stress. Linear regression models compared biomarker concentrations between survivors and controls and with neurocognitive outcomes, adjusting for age, sex, race, body mass index, anti-inflammatory medication, and recent infections...
February 21, 2024: Clinical Cancer Research